Advancing a new generation of treatments for
central nervous system disorders
21 May 2014
NeurOp Selects NP10679 as Development Candidate for SAH
11 Apr 2014
NeurOp Receives Third Year of NIH Funding for Ischemia Research
15 Apr 2013
NeurOp Receives Second Half of NIH Grant for Meeting Schizophrenia Research Mile ...
NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders,
including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of
N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling.
Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented
opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
Learn more about our science.